Abstract: The present invention discloses novel silicon incorporated cyclic compounds of formula I, Wherein Ar1 and Ar2 are individually selected from any aryl group which can be optionally substituted; X is selected from any inorganic anion such as halide, carbonate, sulfate, nitrate or any organic anion selected from acetate, tartarate, citrate, carbonate or organosulfonates such as tosylate, mesylate, triflate; R1 and R2 are individually selected from C1-C8 alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, alkoxyalkyl, aminoalkyl, thioalkyl, haloalkyl or hydroxyalkyl. R1 and R2 together may form a ring which optionally may be substituted or may contain heteroatoms; a pharmaceutical composition comprising a therapeutically effective amount of compounds of general formula I, including geometrical isomers and/or salts thereof along with a drug and optionally along with a carrier or diluent or pharmaceutically acceptable excipient for treating malaria and toxoplasmosis.

Abstract: The present invention discloses a silicon incorporated quinoline of formula (I) wherein, X, Y, A, R1 and R2 are as described. The present invention further discloses a process for the preparation of silicon incorporated quinolines of formula I; a pharmaceutical composition comprising silicon incorporated quinolines of formula (I) or pharmaceutically acceptable salt thereof. The present invention also discloses a method for treating diseases caused by Plasmodium falciparum or other coccidian parasites using the silicon incorporated quinolines of formula I or pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses novel silicon incorporated cyclic compounds of formula I, Wherein Ar1 and Ar2 are individually selected from any aryl group which can be optionally substituted; X is selected from any inorganic anion such as halide, carbonate, sulfate, nitrate or any organic anion selected from acetate, tartarate, citrate, carbonate or organosulfonates such as tosylate, mesylate, triflate; R1 and R2 are individually selected from C1-C8 alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, alkoxyalkyl, aminoalkyl, thioalkyl, haloalkyl or hydroxyalkyl. R1 and R2 together may form a ring which optionally may be substituted or may contain heteroatoms; a pharmaceutical composition comprising a therapeutically effective amount of compounds of general formula I, including geometrical isomers and/or salts thereof along with a drug and optionally along with a carrier or diluent or pharmaceutically acceptable excipient for treating malaria and toxoplasmosis.

Abstract: The present invention discloses a silicon incorporated quinoline of formula (I) wherein, X, Y, A, R1 and R2 are as described. The present invention further discloses a process for the preparation of silicon incorporated quinolines of formula I; a pharmaceutical composition comprising silicon incorporated quinolines of formula (I) or pharmaceutically acceptable salt thereof. The present invention also discloses a method for treating diseases caused by Plasmodium falciparum or other coccidian parasites using the silicon incorporated quinolines of formula I or pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an enantiospecific process for the preparation of (R) and (S) enantiomers of sex pheromones of the long-tailed mealybug with high enantiopurity.

Abstract: The present invention discloses novel antifungal compounds of formula (I), method for preparing these compounds and the use of these compounds as antifungal agents in prevention and treatment of fungal infections, and compositions containing these novel compounds.

Abstract: The present invention relates to an enantiospecific process for the preparation of (R) and (S) enantiomers of sex pheromones of the long-tailed mealybug with high enantiopurity.

Abstract: The invention relates to aza-sila compounds of Formula (I), useful as insect repellants. wherein, ‘A’ is selected from the group consisting of branched or unbranched (C I-CI 2) alkyl, branched or unbranched (CI-CI 2) alkynyl; and substituted or unsubstituted 4 to 6 membered acyclic saturated or unsaturated compounds, wherein the substituents are selected from the group consisting of halogen, hydrogen, (CI-C6) alkyl, aryl, arylalkyl and heterocyclic; or ‘A’ is independently selected from the group consisting of the following moiety: Formula (II) wherein, X and Y are identical or different and independently selected from the group consisting of —C—, —N, —O, and —S; where R1, R2, R3, and R4 are identical or different and are independently selected from the group consisting of hydrogen, halogen, linear or branched (C1-C6) alkyl, aryl, arylalkyl, hydroxyl, and heterocyclic; and wherein, the halogen is selected from the group consisting of —CI, —I, —Br, and —F.

Abstract: The present invention discloses novel Silicon incorporated pyrrole compounds of Formula I having potential anti-bacterial properties. The invention further discloses a process for synthesis of pyrrole compounds with silicon incorporation of Formula I and to the pharmaceutical composition thereof.

Abstract: The present invention discloses novel antifungal compounds of formula (I), method for preparing these compounds and the use of these compounds as antifungal agents in prevention and treatment of fungal infections, and compositions containing these novel compounds.

Abstract: The present invention discloses novel Silicon incorporated pyrrole compounds of Formula I having potential anti-bacterial properties. The invention further discloses a process for synthesis of pyrrole compounds with silicon incorporation of Formula I and to the pharmaceutical composition thereof.

Abstract: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.

Abstract: The invention relates to aza-sila compounds of Formula (I), useful as insect repellants. wherein, ‘A’ is selected from the group consisting of branched or unbranched (C1-C12) alkyl, branched or unbranched (C1-C12) alkynyl; and substituted or unsubstituted 4 to 6 membered acyclic saturated or unsaturated compounds, wherein the substituents are selected from the group consisting of halogen, hydrogen, (C1-C6) alkyl, aryl, arylalkyl and heterocyclic; or ‘A’ is independently selected from the group consisting of the following moiety: Formula (II) wherein, X and Y are identical or different and independently selected from the group consisting of —C—, —N, —O, and —S; where R1, R2, R3, and R4 are identical or different and are independently selected from the group consisting of hydrogen, halogen, linear or branched (C1-C6) alkyl, aryl, arylalkyl, hydroxyl, and heterocyclic; and wherein, the halogen is selected from the group consisting of —Cl, —I, —Br, and —F.

Abstract: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.